AstraZeneca stops zibotentan trial in prostate cancer

AstraZeneca Plc said it is stopping a Phase 3 trial of zibotentan, an endothelin-A receptor antagonist, as a monotherapy against non-metastatic castrate resistant prostate cancer. However a trial of the drug, with chemotherapy, will continue.